Login Register Cart 0
Generic placeholder image

Current Cardiology Reviews

Editor-in-Chief

ISSN (Print): 1573-403X
ISSN (Online): 1875-6557

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
General Review Article

Cirrhotic Cardiomyopathy: The Interplay Between Liver and Cardiac Muscle. How Does the Cardiovascular System React When the Liver is Diseased?

Author(s): Spyros P. Dourakis*, Eleni Geladari, Charalampia Geladari and Natalia Vallianou

Volume 17, Issue 1, 2021

Published on: 09 May, 2019

Article ID: e080323172042 Pages: 7

DOI: 10.2174/1573403X15666190509084519

Price: $65

Abstract

It is widely known that liver cirrhosis, regardless of the etiologies is accompanied by severe hemodynamic changes. The principal pathophysiological mechanisms are the hyperdynamic circulation with increased cardiac output, heart rate along with reduced systemic vascular resistance. Thus, counteractive mechanisms may develop that eventually lead to systolic as well as diastolic dysfunction and rhythm disturbances, in order to keep a steady homeostasis in the human body.

Literally, blunted contractile responsiveness to physical or pharmacological stress, impaired diastolic relaxation and electrophysiological changes, primarily QT interval prolongation, do occur progressively in a cirrhotic patient with no known preexisting cardiac disease. This condition is identified as cirrhotic cardiomyopathy (CCM), an entity different from that seen in alcoholic cardiac muscle disease.

For the past decades, clinicians did study and attempt to understand the pathophysiology and clinical significance of this process. Indeed, various factors have been identified acting at the molecular and cellular level.

Electrocardiography, echocardiography and various serum biomarkers are the main tools that help healthcare practitioners to point to the correct diagnosis.

Noteworthy, the subjects that suffer from cirrhotic cardiomyopathy may progress to heart failure during invasive procedures such as surgery, insertion of a transjugular intrahepatic portosystemic shunting (TIPS) and liver transplantation. Besides, several studies have illustrated that CCM is a contributing factor, or even a precipitant, of hepatorenal syndrome (HRS), a conceivable reversible kidney failure in patients with liver cirrhosis and ascites.

The treatment is the same as it is in the patients with liver cirrhosis and heart failure and there is no particular treatment for cirrhotic cardiomyopathy. Hence, it is of utmost importance to clearly comprehend the pathophysiology of this disease in order to design more accurate diagnostic tools and definitive treatments in a way to prevent the complications of cirrhosis and overt heart failure.

The objective of this review is to describe in a comprehensive way the pathological alterations that occur in the cardiovascular system of cirrhotic patients. It will also point the limitations that remain in the diagnosis and treatment strategies and more importantly, this review will alert the clinicians in the modern era to further observe and record additional pathological changes in this subset of patients.

Keywords: Cirrhosis, cirrhotic cardiomyopathy, systolic dysfunction, diastolic dysfunction, heart failure, TIPS, homeostasis.

Graphical Abstract

[1]
Schuppan D, Afdhal NH. Liver cirrhosis. Lancet 2008; 371(9615): 838-51.
[http://dx.doi.org/10.1016/S0140-6736(08)60383-9] [PMID: 18328931]
[2]
Møller S, Henriksen JH, Bendtsen F. Extrahepatic complications to cirrhosis and portal hypertension: Haemodynamic and homeostatic aspects. World J Gastroenterol 2014; 20(42): 15499-517.
[http://dx.doi.org/10.3748/wjg.v20.i42.15499] [PMID: 25400435]
[3]
Møller S, Bendtsen F. Cirrhotic multiorgan syndrome. Dig Dis Sci 2015; 60(11): 3209-25.
[http://dx.doi.org/10.1007/s10620-015-3752-3] [PMID: 26112989]
[4]
Zhou WC, Zhang QB, Qiao L. Pathogenesis of liver cirrhosis. World J Gastroenterol 2014; 20(23): 7312-24.
[http://dx.doi.org/10.3748/wjg.v20.i23.7312] [PMID: 24966602]
[5]
Martínez-Esparza M, Tristán-Manzano M, Ruiz-Alcaraz AJ, García-Peñarrubia P. Inflammatory status in human hepatic cirrhosis. World J Gastroenterol 2015; 21(41): 11522-41.
[http://dx.doi.org/10.3748/wjg.v21.i41.11522] [PMID: 26556984]
[6]
Kowalski HJ, Abelmann WH. The cardiac output at rest in Laennec’s cirrhosis. J Clin Invest 1953; 32(10): 1025-33.
[http://dx.doi.org/10.1172/JCI102813] [PMID: 13096569]
[7]
Kelbaek H, Rabøl A, Brynjolf I, et al. Haemodynamic response to exercise in patients with alcoholic liver cirrhosis. Clin Physiol 1987; 7(1): 35-41.
[http://dx.doi.org/10.1111/j.1475-097X.1987.tb00631.x] [PMID: 3816110]
[8]
Pozzi M, Carugo S, Boari G, et al. Evidence of functional and structural cardiac abnormalities in cirrhotic patients with and without ascites. Hepatology 1997; 26(5): 1131-7.
[PMID: 9362352]
[9]
Wong F, Liu P, Lilly L, Bomzon A, Blendis L. Role of cardiac structural and functional abnormalities in the pathogenesis of hyperdynamic circulation and renal sodium retention in cirrhosis. Clin Sci (Lond) 1999; 97(3): 259-67.
[http://dx.doi.org/10.1042/cs0970259] [PMID: 10464050]
[10]
Møller S, Henriksen JH. Cardiovascular complications of cirrhosis. Postgrad Med J 2009; 85(999): 44-54.
[PMID: 19240290]
[11]
Zardi EM, Abbate A, Zardi DM, et al. Cirrhotic cardiomyopathy. J Am Coll Cardiol 2010; 56(7): 539-49.
[http://dx.doi.org/10.1016/j.jacc.2009.12.075] [PMID: 20688208]
[12]
Chayanupatkul M, Liangpunsakul S. Cirrhotic cardiomyopathy: Review of pathophysiology and treatment. Hepatol Int 2014; 8(3): 308-15.
[http://dx.doi.org/10.1007/s12072-014-9531-y] [PMID: 25221635]
[13]
11. Myers RP, Lee SS. Cirrhotic cardiomyopathy and liver transplantation. Liver Transpl 2000; 6(4): S44-52.
[PMID: 10915191]
[14]
Sampathkumar P, Lerman A, Kim BY, et al. Post-liver transplantation myocardial dysfunction. Liver Transpl Surg 1998; 4(5): 399-403.
[http://dx.doi.org/10.1002/lt.500040513] [PMID: 9724477]
[15]
Moreau R, Hadengue A, Soupison T, et al. Abnormal pressor response to vasopressin in patients with cirrhosis: Evidence for impaired buffering mechanisms. Hepatology 1990; 12(1): 7-12.
[http://dx.doi.org/10.1002/hep.1840120103] [PMID: 2373486]
[16]
Wong F, Siu S, Liu P, Blendis LM. Brain natriuretic peptide: Is it a predictor of cardiomyopathy in cirrhosis? Clin Sci (Lond) 2001; 101(6): 621-8.
[http://dx.doi.org/10.1042/cs1010621] [PMID: 11724649]
[17]
Henriksen JH, Gøtze JP, Fuglsang S, Christensen E, Bendtsen F, Møller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 2003; 52(10): 1511-7.
[http://dx.doi.org/10.1136/gut.52.10.1511] [PMID: 12970147]
[18]
Pateron D, Beyne P, Laperche T, et al. Elevated circulating cardiac troponin I in patients with cirrhosis. Hepatology 1999; 29(3): 640-3.
[http://dx.doi.org/10.1002/hep.510290332] [PMID: 10051461]
[19]
Bernardi M, Calandra S, Colantoni A, et al. Q-T interval prolongation in cirrhosis: Prevalence, relationship with severity, and etiology of the disease and possible pathogenetic factors. Hepatology 1998; 27(1): 28-34.
[http://dx.doi.org/10.1002/hep.510270106] [PMID: 9425913]
[20]
Baik SK, Fouad TR, Lee SS. Cirrhotic cardiomyopathy. Orphanet J Rare Dis 2007; 2: 15. [PUBMED: 17389039].
[http://dx.doi.org/10.1186/1750-1172-2-15] [PMID: 17389039]
[21]
Padillo J, Rioja P, Muñoz-Villanueva MC, et al. BNP as marker of heart dysfunction in patients with liver cirrhosis. Eur J Gastroenterol Hepatol 2010; 22(11): 1331-6.
[http://dx.doi.org/10.1097/MEG.0b013e32833e6b2a] [PMID: 20729741]
[22]
Arroyo V, Terra C, Ginès P. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J Hepatol 2007; 46(5): 935-46.
[http://dx.doi.org/10.1016/j.jhep.2007.02.001] [PMID: 17391801]
[23]
Milani A, Zaccaria R, Bombardieri G, Gasbarrini A, Pola P. Cirrhotic cardiomyopathy. Dig Liver Dis 2007; 39(6): 507-15.
[http://dx.doi.org/10.1016/j.dld.2006.12.014] [PMID: 17383244]
[24]
Arroyo V, Ginès P, Gerbes AL, et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis. International Ascites Club. Hepatology 1996; 23(1): 164-76.
[http://dx.doi.org/10.1002/hep.510230122]
[25]
Ruiz-del-Arbol L, Urman J, Fernández J, et al. Systemic, renal, and hepatic hemodynamic derangement in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 2003; 38(5): 1210-8.
[http://dx.doi.org/10.1053/jhep.2003.50447] [PMID: 14578859]
[26]
Lee SS. Cardiac dysfunction in spontaneous bacterial peritonitis: A manifestation of cirrhotic cardiomyopathy? Hepatology 2003; 38(5): 1089-91.
[http://dx.doi.org/10.1053/jhep.2003.50489] [PMID: 14578846]
[27]
Zambruni A, Trevisani F, Caraceni P, Bernardi M. Cardiac electrophysiological abnormalities in patients with cirrhosis. J Hepatol 2006; 44(5): 994-1002.
[http://dx.doi.org/10.1016/j.jhep.2005.10.034] [PMID: 16510203]
[28]
Páll A, Czifra A, Vitális Z, Papp M, Paragh G, Szabó Z. Pathophysiological and clinical approach to cirrhotic cardiomyopathy. J Gastrointestin Liver Dis 2014; 23(3): 301-10.
[http://dx.doi.org/10.15403/jgld.2014.1121.233.apac] [PMID: 25267959]
[29]
Wong F. Cirrhotic cardiomyopathy. Hepatol Int 2009; 3(1): 294-304.
[http://dx.doi.org/10.1007/s12072-008-9109-7] [PMID: 19669380]
[30]
Timoh T, Protano MA, Wagman G, Bloom M, Vittorio TJ. A perspective on cirrhotic cardiomyopathy. Transplant Proc 2011; 43(5): 1649-53.
[http://dx.doi.org/10.1016/j.transproceed.2011.01.188] [PMID: 21693251]
[31]
Laleman W, Landeghem L, Wilmer A, Fevery J, Nevens F. Portal hypertension: from pathophysiology to clinical practice. Liver Int 2005; 25(6): 1079-90.
[http://dx.doi.org/10.1111/j.1478-3231.2005.01163.x] [PMID: 16343056]
[32]
Abraldes JG, Iwakiri Y, Loureiro-Silva M, Haq O, Sessa WC, Groszmann RJ. Mild increases in portal pressure upregulate vascular endothelial growth factor and endothelial nitric oxide synthase in the intestinal microcirculatory bed, leading to a hyperdynamic state. Am J Physiol Gastrointest Liver Physiol 2006; 290(5): G980-7.
[http://dx.doi.org/10.1152/ajpgi.00336.2005] [PMID: 16603731]
[33]
Wiest R, Groszmann RJ. The paradox of nitric oxide in cirrhosis and portal hypertension: too much, not enough. Hepatology 2002; 35(2): 478-91.
[http://dx.doi.org/10.1053/jhep.2002.31432] [PMID: 11826425]
[34]
Henriksen JH, Møller S, Schifter S, et al. High arterial compliance in cirrhosis is related to elevated circulating calcitonin gene-related peptide (CGRP) and low adrenaline,but not to activated vasoconstrictor systems. Gut 2001; 49: 112-8.
[http://dx.doi.org/10.1136/gut.49.1.112] [PMID: 11413119]
[35]
Møller S, Henriksen JH. Ascites and Renal Dysfunction in Liver Disease 2005; 139-55.
[36]
Møller S, Burchardt H, Øgard CG, Schiødt FV, Lund JO. Pulmonary blood volume and transit time in cirrhosis: Relation to lung function. Liver Int 2006; 26(9): 1072-8.
[http://dx.doi.org/10.1111/j.1478-3231.2006.01343.x] [PMID: 17032407]
[37]
Schrier RW. Water and sodium retention in edematous disorders: role of vasopressin and aldosterone. Am J Med 2006; 119(7)(Suppl. 1): S47-53.
[http://dx.doi.org/10.1016/j.amjmed.2006.05.007] [PMID: 16843085]
[38]
Brinch K, Møller S, Bendtsen F, Becker U, Henriksen JH. Plasma volume expansion by albumin in cirrhosis. Relation to blood volume distribution, arterial compliance and severity of disease. J Hepatol 2003; 39(1): 24-31.
[http://dx.doi.org/10.1016/S0168-8278(03)00160-0] [PMID: 12821040]
[39]
Gould L, Shariff M, Zahir M, Di Lieto M. Cardiac hemodynamics in alcoholic patients with chronic liver disease and a presystolic gallop. J Clin Invest 1969; 48(5): 860-8.
[http://dx.doi.org/10.1172/JCI106044] [PMID: 4180971]
[40]
Kelbaek H, Eriksen J, Brynjolf I, et al. Cardiac performance in patients with asymptomatic alcoholic cirrhosis of the liver. Am J Cardiol 1984; 54(7): 852-5.
[http://dx.doi.org/10.1016/S0002-9149(84)80220-9] [PMID: 6486037]
[41]
Wong F, Girgrah N, Graba J, Allidina Y, Liu P, Blendis L. The cardiac response to exercise in cirrhosis. Gut 2001; 49(2): 268-75.
[http://dx.doi.org/10.1136/gut.49.2.268] [PMID: 11454805]
[42]
Limas CJ, Guiha NH, Lekagul O, Cohn JN. Impaired left ventricular function in alcoholic cirrhosis with ascites. Ineffectiveness of ouabain. Circulation 1974; 49(4): 754-60.
[http://dx.doi.org/10.1161/01.CIR.49.4.755] [PMID: 4361711]
[43]
Møller S, Henriksen JH. Cirrhotic cardiomyopathy: A pathophysiological review of circulatory dysfunction in liver disease. Heart 2002; 87(1): 9-15.
[http://dx.doi.org/10.1136/heart.87.1.9] [PMID: 11751653]
[44]
Baldassarre M, Giannone FA, Napoli L, et al. The endocannabinoid system in advanced liver cirrhosis: Pathophysiological implication and future perspectives. Liver Int 2013; 33(9): 1298-308. [PUBMED: 23890208].
[http://dx.doi.org/10.1111/liv.12263] [PMID: 23890208]
[45]
van Obbergh L, Vallieres Y, Blaise G. Cardiac modifications occurring in the ascitic rat with biliary cirrhosis are nitric oxide related. J Hepatol 1996; 24(6): 747-52. [PUBMED: 8835751].
[http://dx.doi.org/10.1016/S0168-8278(96)80272-8] [PMID: 8835751]
[46]
Moller S, Henriksen JH. The systemic circulation in cirrhosis. Ascites and Renal Dysfunction in Liver Disease 2005; pp. 139-55.
[http://dx.doi.org/10.1002/9780470987476.ch11]
[47]
Gerbes AL, Remien J, Jüngst D, Sauerbruch T, Paumgartner G. Evidence for down-regulation of beta-2-adrenoceptors in cirrhotic patients with severe ascites. Lancet 1986; 1(8495): 1409-11.
[http://dx.doi.org/10.1016/S0140-6736(86)91556-4] [PMID: 2872517]
[48]
Hausdorff WP, Caron MG, Lefkowitz RJ. Turning off the signal: desensitization of beta-adrenergic receptor function. FASEB J 1990; 4(11): 2881-9.
[http://dx.doi.org/10.1096/fasebj.4.11.2165947] [PMID: 2165947]
[49]
García-Estañ J, Ortiz MC, Lee SS. Nitric oxide and renal and cardiac dysfunction in cirrhosis. Clin Sci (Lond) 2002; 102(2): 213-22.
[http://dx.doi.org/10.1042/cs1020213] [PMID: 11834141]
[50]
Aurigemma GP, Gaasch WH. Clinical practice. Diastolic heart failure. N Engl J Med 2004; 351(11): 1097-105.
[http://dx.doi.org/10.1056/NEJMcp022709] [PMID: 15356307]
[51]
Little WC, Kitzman DW, Cheng CP. Diastolic dysfunction as a cause of exercise intolerance. Heart Fail Rev 2000; 5(4): 301-6.
[http://dx.doi.org/10.1023/A:1026503028065] [PMID: 11498643]
[52]
Ortiz-Olvera NX, Castellanos-Pallares G, Gómez-Jiménez LM, et al. Anatomical cardiac alterations in liver cirrhosis: an autopsy study. Ann Hepatol 2011; 10(3): 321-6.
[PMID: 21677334]
[53]
Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 2009; 22(2): 107-33.
[http://dx.doi.org/10.1016/j.echo.2008.11.023] [PMID: 19187853]
[54]
Wiest R, Garcia-Tsao G. Bacterial translocation (BT) in cirrhosis. Hepatology 2005; 41(3): 422-33.
[http://dx.doi.org/10.1002/hep.20632] [PMID: 15723320]
[55]
Karagiannakis DS, Vlachogiannakos J, Anastasiadis G, Vafiadis-Zouboulis I, Ladas SD. Frequency and severity of cirrhotic cardiomyopathy and its possible relationship with bacterial endotoxemia. Dig Dis Sci 2013; 58(10): 3029-36.
[http://dx.doi.org/10.1007/s10620-013-2693-y] [PMID: 23907333]
[56]
Fields NG, Yuan BX, Leenen FH. Sodium-induced cardiac hypertrophy. Cardiac sympathetic activity versus volume load. Circ Res 1991; 68(3): 745-55.
[http://dx.doi.org/10.1161/01.RES.68.3.745] [PMID: 1835910]
[57]
Takeda Y, Yoneda T, Demura M, Miyamori I, Mabuchi H. Sodium-induced cardiac aldosterone synthesis causes cardiac hypertrophy. Endocrinology 2000; 141(5): 1901-4.
[http://dx.doi.org/10.1210/endo.141.5.7529] [PMID: 10803602]
[58]
Finucci G, Desideri A, Sacerdoti D, et al. Left ventricular diastolic function in liver cirrhosis. Scand J Gastroenterol 1996; 31(3): 279-84.
[http://dx.doi.org/10.3109/00365529609004879] [PMID: 8833359]
[59]
Laffi G, Barletta G, La Villa G, et al. Altered cardiovascular responsiveness to active tilting in nonalcoholic cirrhosis. Gastroenterology 1997; 113(3): 891-8.
[http://dx.doi.org/10.1016/S0016-5085(97)70184-7] [PMID: 9287981]
[60]
Ho CY. Echocardiographic Assessment of Diastolic Function. Solomon SD, editor. Essential Echocardiography 2006; pp. 119-31.
[61]
Cazzaniga M, Salerno F, Pagnozzi G, et al. Diastolic dysfunction is associated with poor survival in patients with cirrhosis with transjugular intrahepatic portosystemic shunt. Gut 2007; 56(6): 869-75.
[http://dx.doi.org/10.1136/gut.2006.102467] [PMID: 17135305]
[62]
Møller S, Bernardi M. Interactions of the heart and the liver. Eur Heart J 2013; 34(36): 2804-11.
[http://dx.doi.org/10.1093/eurheartj/eht246] [PMID: 23853073] [http://dx.doi.org/10.1002/hep.510270106] [PMID: 9425913]
[63]
Zambruni A, Di Micoli A, Lubisco A, Domenicali M, Trevisani F, Bernardi M. QT interval correction in patients with cirrhosis. J Cardiovasc Electrophysiol 2007; 18(1): 77-82.
[http://dx.doi.org/10.1111/j.1540-8167.2006.00622.x] [PMID: 17229304]
[64]
Mohamed R, Forsey PR, Davies MK, Neuberger JM. Effect of liver transplantation on QT interval prolongation and autonomic dysfunction in end-stage liver disease. Hepatology 1996; 23(5): 1128-34.
[http://dx.doi.org/10.1002/hep.510230529] [PMID: 8621144]
[65]
Ytting H, Henriksen JH, Fuglsang S, Bendtsen F, Møller S. Prolonged Q-T(c) interval in mild portal hypertensive cirrhosis. J Hepatol 2005; 43(4): 637-44.
[http://dx.doi.org/10.1016/j.jhep.2005.04.015] [PMID: 16083986]
[66]
Mozos I. Arrhythmia risk in liver cirrhosis. World J Hepatol 2015; 7(4): 662-72.
[http://dx.doi.org/10.4254/wjh.v7.i4.662] [PMID: 25866603]
[67]
Batchvarov V, Camm AJ. QT dispersion: Measurement and interpretation. UpToDate 2014.
[68]
Shin WJ, Kim YK, Song JG, et al. Alterations in QT interval in patients undergoing living donor liver transplantation. Transplant Proc 2011; 43(1): 170-3.
[http://dx.doi.org/10.1016/j.transproceed.2010.12.002] [PMID: 21335179]
[69]
Zambruni A, Trevisani F, Di Micoli A, et al. Effect of chronic beta-blockade on QT interval in patients with liver cirrhosis. J Hepatol 2008; 48(3): 415-21.
[http://dx.doi.org/10.1016/j.jhep.2007.11.012] [PMID: 18194821]
[70]
Ruiz-del-Arbol L, Monescillo A, Jimenéz W, Garcia-Plaza A, Arroyo V, Rodés J. Paracentesis-induced circulatory dysfunction: mechanism and effect on hepatic hemodynamics in cirrhosis. Gastroenterology 1997; 113(2): 579-86.
[http://dx.doi.org/10.1053/gast.1997.v113.pm9247479] [PMID: 9247479]
[71]
Hendrickse MT, Triger DR. Peripheral and cardiovascular autonomic impairment in chronic liver disease: Prevalence and relation to hepatic function. J Hepatol 1992; 16(1-2): 177-83.
[http://dx.doi.org/10.1016/S0168-8278(05)80112-6] [PMID: 1336506]
[72]
Gassanov N, Caglayan E, Semmo N, Massenkeil G, Er F. Cirrhotic cardiomyopathy: A cardiologist’s perspective. World J Gastroenterol 2014; 20(42): 15492-8.
[http://dx.doi.org/10.3748/wjg.v20.i42.15492] [PMID: 25400434]
[73]
Bernardi M. Cirrhotic cardiomyopathy. Clin Liver Dis (Hoboken) 2013; 2(3): 99-101.
[http://dx.doi.org/10.1002/cld.141] [PMID: 30992835]
[74]
Alqahtani SA, Fouad TR, Lee SS. Cirrhotic cardiomyopathy. Semin Liver Dis 2008; 28(1): 59-69.
[http://dx.doi.org/10.1055/s-2008-1040321] [PMID: 18293277]
[75]
Wiese S, Hove JD, Bendtsen F, Møller S. Cirrhotic cardiomyopathy: pathogenesis and clinical relevance. Nat Rev Gastroenterol Hepatol 2014.
[PMID: 24217347] [http://dx.doi.org/10.1038/nrgastro.2013.210]
[76]
Henriksen JH, Bendtsen F, Hansen EF, Møller S. Acute non-selective beta-adrenergic blockade reduces prolonged frequency-adjusted Q-T interval (QTc) in patients with cirrhosis. J Hepatol 2004; 40(2): 239-46. [PubMed: 14739094]
[http://dx.doi.org/10.1016/j.jhep.2003.10.026] [PMID: 14739094]
[77]
Wong F, Salerno F. Beta-blockers in cirrhosis: Friend and foe? Hepatology 2010; 52(3): 811-3. [PubMed: 20812354]
[http://dx.doi.org/10.1002/hep.23852] [PMID: 20812354]
[78]
Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999; 341(10): 709-17.
[http://dx.doi.org/10.1056/NEJM199909023411001] [PMID: 10471456]

Rights & Permissions Print Cite
Article Metrics
21
1
© 2024 Bentham Science Publishers | Privacy Policy